Olema Pharmaceuticals CFO files initial ownership

Olema Pharmaceuticals, Inc. filed an initial statement of beneficial ownership for its Chief Financial Officer, Jason O'Byrne.

Rhea-AI Filing Summary

Olema Pharmaceuticals, Inc. filed an initial statement of beneficial ownership for its Chief Financial Officer, Jason O'Byrne. The filing reports no equity transactions and shows no reported holdings or derivative positions at this time.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does Olema Pharmaceuticals (OLMA) report in Jason O'Byrne's Form 3?

Olema Pharmaceuticals reports that Chief Financial Officer Jason O'Byrne has filed an initial Form 3 showing no reported equity holdings or derivative positions and no transactions in Olema securities as of the filing.

Does the OLMA Form 3 for Jason O'Byrne show any stock transactions?

No. The Form 3 for Olema’s CFO shows zero buy, sell, acquire, or dispose transactions. The transaction summary lists no shares traded, no exercises, and no gifts at the time of this initial ownership report.

Are any Olema Pharmaceuticals (OLMA) shares or options reported as held by Jason O'Byrne?

No holdings are reported. The Form 3 indicates no non-derivative holdings and an empty derivative positions section, meaning no Olema shares or equity derivatives are disclosed as owned in this filing.

What is Jason O'Byrne’s role at Olema Pharmaceuticals (OLMA) in this Form 3?

The filing identifies Jason O'Byrne as an officer of Olema Pharmaceuticals, serving as Chief Financial Officer. He is not reported as a director or 10% beneficial owner in this initial ownership statement.

Does the OLMA Form 3 mention any Rule 10b5-1 trading plan for Jason O'Byrne?

No Rule 10b5-1 plan is indicated. The data shows the 10b5-1 status field is null, and there are no footnotes describing a trading plan associated with this initial ownership filing.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding Insider Trading Forms →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/13/2026 - 04:34 PM Accepted by SEC EDGAR 08/13/2026 - 04:33 PM Learn about SEC filing dates

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

O'Byrne Jason

(Last) (First) (Middle)

C/O OLEMA PHARMACEUTICALS, INC.

780 BRANNAN ST

(Street)

SAN FRANCISCO CALIFORNIA 94103

(City) (State) (Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
08/11/2026

3. Issuer Name and Ticker or Trading Symbol
Olema Pharmaceuticals, Inc. [ OLMA ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CHIEF FINANCIAL OFFICER

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

No securities are beneficially owned.

	/s/ Shawnte Mitchell, Attorney-in-Fact	08/13/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)